Central Serous Chorioretinopathy: Update on Pathophysiology and Treatment

Survey of Ophthalmology

Volumn 58, Issue 2, 2013, Pages 103-126

  Nicholson, Benjamin ^a   Noble, Jason ^b,c   Forooghian, Farzin ^d   Meyerle, Catherine ^a  

^a NATIONAL EYE INSTITUTE   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Central serous chorioretinopathy; Corticosteroids; Diffuse retinal pigment epitheliopathy; Fundus autofluorescence; Indocyanine green angiography; Optical coherence tomography; Photodynamic therapy

Indexed keywords

ACETAZOLAMIDE; ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; CORTICOSTEROID; CYTOKINE; FINASTERIDE; GLUCOCORTICOID; KETOCONAZOLE; MIFEPRISTONE; RANIBIZUMAB; RIFAMPICIN; VERTEPORFIN;

ADAPTIVE OPTICS; ARGON LASER; AUTOFLUORESCENCE IMAGING; CENTRAL SEROUS RETINOPATHY; CONTRAST SENSITIVITY; DIODE LASER; DRUG WITHDRAWAL; ELECTRORETINOGRAPHY; HELICOBACTER INFECTION; HUMAN; HYPERTENSION; INDOCYANINE GREEN ANGIOGRAPHY; LASER COAGULATION; MALE TYPE ALOPECIA; MICROPERIMETRY; MULTIFOCAL ELECTRORETINOGRAPHY; OPTICAL COHERENCE TOMOGRAPHY; OPTICS; PATHOPHYSIOLOGY; PERIMETRY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REITER SYNDROME; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA PIGMENT EPITHELIOPATHY; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL FLUID; SUBRETINAL NEOVASCULARIZATION; TRANSPUPILLARY THERMOTHERAPY; VISUAL ACUITY;

CENTRAL SEROUS CHORIORETINOPATHY; COLORING AGENTS; FLUORESCEIN ANGIOGRAPHY; HUMANS; INDOCYANINE GREEN; LASER COAGULATION; PHOTOCHEMOTHERAPY; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL FIELD TESTS;

EID: 84873590913     PISSN: 00396257     EISSN: 18793304     Source Type: Journal    
DOI: 10.1016/j.survophthal.2012.07.004     Document Type: Review

References (242)

1. US Preventive Services Task Force Ratings. Grade Definitions. Guide to Clinical Preventive Services, Third Edition: Periodic Updates. 2000-2003. Available at Accessed 10/10/2011. http://www.uspreventiveservicestaskforce.org/3rduspstf/ratings.htm.
2. Abu el-Asrar A.M. Central serous chorioretinopathy complicating systemic corticosteroid therapy. Eur J Ophthalmol 1997, 7:297-300.
3. Ahnoux-Zabsonre A., Quaranta M., Mauget-Faysse M. [Prevalence of Helicobacter pylori in central serous chorioretinopathy and diffuse retinal epitheliopathy: a complementary study]. J Fr Ophtalmol 2004, 27:1129-1133.
4. Aliferis K., Petropoulos I.K., Farpour B., et al. Should central serous chorioretinopathy be added to the list of ocular side effects of phosphodiesterase 5 inhibitors?. Ophthalmologica 2012, 227:85-89.
5. Amalric P., Gourinat P., Rebiere P. [Is central serous choroiditis sometimes hereditary?]. Bull Soc Ophtalmol Fr 1971, 71:163-168.
6. Anupama B., Puthran N., Hegde V., et al. Plantar fasciitis and impaired vision: a case report. Foot (Edinb) 2010, 20:151-153.
7. Arevalo J.F., Espinoza J.V. Single-session combined photodynamic therapy with verteporfin and intravitreal anti-vascular endothelial growth factor therapy for chronic central serous chorioretinopathy: a pilot study at 12-month follow-up. Graefes Arch Clin Exp Ophthalmol 2011, 249:1159-1166.
8. Arndt C., Sari A., Ferre M., et al. Electrophysiological effects of corticosteroids on the retinal pigment epithelium. Invest Ophthalmol Vis Sci 2001, 42:472-475.
9. Artunay O., Yuzbasioglu E., Rasier R., et al. Intravitreal bevacizumab in treatment of idiopathic persistent central serous chorioretinopathy: a prospective, controlled clinical study. Curr Eye Res 2010, 35:91-98.
10. Asensio-Sanchez V.M., Rodriguez-Delgado B., Garcia-Herrero E., et al. [Central serous chorioretinopathy as an extradigestive manifestation of Helicobacter pylori gastric infection]. Arch Soc Esp Oftalmol 2008, 83:177-182.
11. Bae S.H., Heo J.W., Kim C., et al. A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy. Am J Ophthalmol 2011, 152(5):784-792.
12. Balakrishnan S., Apsingi S., Manjure S.B. Sudden loss of visual acuity following intra-articular steroid injection in to the knee joint: a case report. Cases J 2008, 1:428.
13. Bandello F, Lanzeto P, Furlan F, et al. Non-visible sub-threshold micropulse diode laser treatment of idiopathic central serous chorioretinopathy. A pilot study. Invest Ophthalmol Vis Sci. 2003;44:E-abstract 4858.
14. Baran N.V., Gurlu V.P., Esgin H. Long-term macular function in eyes with central serous chorioretinopathy. Clin Experiment Ophthalmol 2005, 33:369-372.
15. Barnes P.J. Corticosteroid effects on cell signalling. Eur Respir J 2006, 27:413-426.
16. Bastl C.P. Regulation of cation transport by low doses of glucocorticoids in in vivo adrenalectomized rat colon. J Clin Invest 1987, 80:348-356.
17. Battaglia Parodi M., Da Pozzo S., Ravalico G. Photodynamic therapy in chronic central serous chorioretinopathy. Retina 2003, 23:235-237.
18. Baumal C.R., Martidis A., Truong S.N. Central serous chorioretinopathy associated with periocular corticosteroid injection treatment for HLA-B27-associated iritis. Arch Ophthalmol 2004, 122:926-928.
19. Bouzas E.A., Scott M.H., Mastorakos G., et al. Central serous chorioretinopathy in endogenous hypercortisolism. Arch Ophthalmol 1993, 111:1229-1233.
20. Bouzas E.A., Karadimas P., Pournaras C.J. Central serous chorioretinopathy and glucocorticoids. Surv Ophthalmol 2002, 47:431-448.
21. Brancato R., Scialdone A., Pece A., et al. Eight-year follow-up of central serous chorioretinopathy with and without laser treatment. Graefes Arch Clin Exp Ophthalmol 1987, 225:166-168.
22. Browning D.J. Nadolol in the treatment of central serous retinopathy. Am J Ophthalmol 1993, 116:770-771.
23. Bujarborua D. Long-term follow-up of idiopathic central serous chorioretinopathy without laser. Acta Ophthalmol Scand 2001, 79:417-421.
24. Burumcek E., Mudun A., Karacorlu S., et al. Laser photocoagulation for persistent central serous retinopathy: results of long-term follow-up. Ophthalmology 1997, 104:616-622.
25. Byrne M.F., Kerrigan S.W., Corcoran P.A., et al. Helicobacter pylori binds von Willebrand factor and interacts with GPIb to induce platelet aggregation. Gastroenterology 2003, 124:1846-1854.
26. Caccavale A., Imparato M., Romanazzi F., et al. A new strategy of treatment with low-dosage acetyl salicylic acid in patients affected by central serous chorioretinopathy. Med Hypotheses 2009, 73:435-437.
27. Caccavale A., Romanazzi F., Imparato M., et al. Low-dose aspirin as treatment for central serous chorioretinopathy. Clin Ophthalmol 2010, 4:899-903.
28. Caccavale A., Romanazzi F., Imparato M., et al. Central serous chorioretinopathy: a pathogenetic model. Clin Ophthalmol 2011, 5:239-243.
29. Cardillo Piccolino F., Eandi C.M., Ventre L., et al. Photodynamic therapy for chronic central serous chorioretinopathy. Retina 2003, 23:752-763.
30. Carmeliet P., Jain R.K. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011, 473:298-307.
31. Carneiro A.M., Silva R.M., Veludo M.J., et al. Ranibizumab treatment for choroidal neovascularization from causes other than age-related macular degeneration and pathological myopia. Ophthalmologica 2011, 225:81-88.
32. Carvalho-Recchia C.A., Yannuzzi L.A., Negrao S., et al. Corticosteroids and central serous chorioretinopathy. Ophthalmology 2002, 109:1834-1837.
33. Chan W.M., Lam D.S., Lai T.Y., et al. Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol 2003, 87:1453-1458.
34. Chan W.M., Lai T.Y., Liu D.T., et al. Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin. Am J Ophthalmol 2007, 143:977-983.
35. Chan W.M., Lai T.Y., Lai R.Y., et al. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology 2008, 115:1756-1765.
36. Chan W.M., Lai T.Y., Lai R.Y., et al. Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: one-year results of a prospective study. Retina 2008, 28:85-93.
37. Chang M.A., Bressler S.B. Photodynamic therapy for chronic pigment epithelial detachment in central serous chorioretinopathy. Can J Ophthalmol 2009, 44:221-222.
38. Chappelow A.V., Marmor M.F. Multifocal electroretinogram abnormalities persist following resolution of central serous chorioretinopathy. Arch Ophthalmol 2000, 118:1211-1215.
39. Chen S.N., Hwang J.F., Tseng L.F., et al. Subthreshold diode micropulse photocoagulation for the treatment of chronic central serous chorioretinopathy with juxtafoveal leakage. Ophthalmology 2008, 115:2229-2234.
40. Chumbley L.C., Frank R.N. Central serous retinopathy and pregnancy. Am J Ophthalmol 1974, 77:158-160.
41. Cotticelli L., Borrelli M., D'Alessio A.C., et al. Central serous chorioretinopathy and Helicobacter pylori. Eur J Ophthalmol 2006, 16:274-278.
42. Cousins L., Rigg L., Hollingsworth D., et al. Qualitative and quantitative assessment of the circadian rhythm of cortisol in pregnancy. Am J Obstet Gynecol 1983, 145:411-416.
43. Cox S.N., Hay E., Bird A.C. Treatment of chronic macular edema with acetazolamide. Arch Ophthalmol 1988, 106:1190-1195.
44. Desai U.R., Alhalel A.A., Campen T.J., et al. Central serous chorioretinopathy in African Americans. J Natl Med Assoc 2003, 95:553-559.
45. Eandi C.M., Chung J.E., Cardillo-Piccolino F., et al. Optical coherence tomography in unilateral resolved central serous chorioretinopathy. Retina 2005, 25:417-421.
46. Ehrlich R., Mawer N.P., Mody C.H., et al. Visual function following photodynamic therapy for central serous retinopathy: a comparison of automated macular microperimery versus best corrected visual acuity. Clin Experiment Ophthalmol 2012, 40(1):32-39.
47. Ezra N., Taban M., Behroozan D. Central serous chorioretinopathy associated with topical corticosteroids in a patient with psoriasis. J Drugs Dermatol 2011, 10:918-921.
48. Fernandez C.F., Mendoza A.J., Arevalo J.F. Central serous chorioretinopathy associated with topical dermal corticosteroids. Retina 2004, 24:471-474.
49. Ficker L., Vafidis G., While A., et al. Long-term follow-up of a prospective trial of argon laser photocoagulation in the treatment of central serous retinopathy. Br J Ophthalmol 1988, 72:829-834.
50. Folk J.C., Thompson H.S., Han D.P., et al. Visual function abnormalities in central serous retinopathy. Arch Ophthalmol 1984, 102:1299-1302.
51. Forooghian F., Meleth A.D., Cukras C., et al. Finasteride for chronic central serous chorioretinopathy. Retina 2011, 31:766-771.
52. Fraunfelder F.W., Fraunfelder F.T. Central serous chorioretinopathy associated with sildenafil. Retina 2008, 28:606-609.
53. French D.D., Margo C.E. Central serous chorioretinopathy and phosphodiesterase-5 inhibitors: a case-control postmarketing surveillance study. Retina 2010, 30:271-274.
54. Fujimoto H., Gomi F., Wakabayashi T., et al. Morphologic changes in acute central serous chorioretinopathy evaluated by Fourier-domain optical coherence tomography. Ophthalmology 2008, 115:1494-1500. 500 e1-2.
55. Fujita K., Yuzawa M., Mori R. Retinal sensitivity after photodynamic therapy with half-dose verteporfin for chronic central serous chorioretinopathy: short-term results. Retina 2011, 31:772-778.
56. Furuta M., Iida T., Kishi S. Foveal thickness can predict visual outcome in patients with persistent central serous chorioretinopathy. Ophthalmologica 2009, 223:28-31.
57. Garg S.P., Dada T., Talwar D., et al. Endogenous cortisol profile in patients with central serous chorioretinopathy. Br J Ophthalmol 1997, 81:962-964.
58. Gass J.D. Pathogenesis of disciform detachment of the neuroepithelium. Am J Ophthalmol 1967, 63(Suppl):1-139.
59. Gass J.D. Bullous retinal detachment. An unusual manifestation of idiopathic central serous choroidopathy. Am J Ophthalmol 1973, 75:810-821.
60. Gass J.D. Photocoagulation treatment of idiopathic central serous choroidopathy. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol 1977, 83:456-467.
61. Gelber G.S., Schatz H. Loss of vision due to central serous chorioretinopathy following psychological stress. Am J Psychiatry 1987, 144:46-50.
62. Gemenetzi M., De Salvo G., Lotery A.J. Central serous chorioretinopathy: an update on pathogenesis and treatment. Eye (Lond) 2010, 24:1743-1756.
63. Gilbert C.M., Owens S.L., Smith P.D., et al. Long-term follow-up of central serous chorioretinopathy. Br J Ophthalmol 1984, 68:815-820.
64. Giusti C. [Central serous chorioretinopathy: a new extragastric manifestation of Helicobacter pylori? Analysis of a clinical case]. Clin Ter 2001, 152:393-397.
65. Giusti C. Association of Helicobacter pylori with central serous chorioretinopathy: hypotheses regarding pathogenesis. Med Hypotheses 2004, 63:524-527.
66. Golshahi A., Klingmuller D., Holz F.G., et al. Ketoconazole in the treatment of central serous chorioretinopathy: a pilot study. Acta Ophthalmol 2010, 88(5):576-581.
67. Gunther J.B., Altaweel M.M. Bevacizumab (Avastin) for the treatment of ocular disease. Surv Ophthalmol 2009, 54:372-400.
68. Gupta P., Gupta V., Dogra M.R., et al. Morphological changes in the retinal pigment epithelium on spectral-domain OCT in the unaffected eyes with idiopathic central serous chorioretinopathy. Int Ophthalmol 2010, 30:175-181.
69. Hadcock J.R., Malbon C.C. Regulation of beta-adrenergic receptors by "permissive" hormones: glucocorticoids increase steady-state levels of receptor mRNA. Proc Natl Acad Sci USA 1988, 85:8415-8419.
70. Haik G.M., Perez L.F., Murtagh J.J. Central serous retinopathy. Consecutive development in daughter and mother. Am J Ophthalmol 1968, 65:612-615.
71. Haimovici R., Gragoudas E.S., Duker J.S., et al. Central serous chorioretinopathy associated with inhaled or intranasal corticosteroids. Ophthalmology 1997, 104:1653-1660.
72. Haimovici R., Rumelt S., Melby J. Endocrine abnormalities in patients with central serous chorioretinopathy. Ophthalmology 2003, 110:698-703.
73. Haimovici R., Koh S., Gagnon D.R., et al. Risk factors for central serous chorioretinopathy: a case-control study. Ophthalmology 2004, 111:244-249.
74. Harada T., Harada K. Six cases of central serous choroidopathy induced by systemic corticosteroid therapy. Doc Ophthalmol 1985, 60:37-44.
75. Harrington D.O. Psychosomatic interrelationships in ophthalmology. Am J Ophthalmol 1948, 31:1241-1251.
76. Heinrich M.R. [Central serous retinopathy and alpha-blockaders]. Bull Soc Ophtalmol Fr 1974, 74:681-683.
77. Horniker E. Su di una forma retinite centrale di origine vasoneurotica (retinite central capillaro spastica). Ann Otal 1927, 55:578-600.
78. Hussain N., Khanna R., Hussain A., Das T. Transpupillary thermotherapy for chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 2006, 244:1045-1051.
79. Iijima H., Iida T., Murayama K., et al. Plasminogen activator inhibitor 1 in central serous chorioretinopathy. Am J Ophthalmol 1999, 127:477-478.
80. Imamura Y., Fujiwara T., Margolis R., et al. Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy. Retina 2009, 29:1469-1473.
81. Imamura Y., Fujiwara T., Spaide R.F. Fundus autofluorescence and visual acuity in central serous chorioretinopathy. Ophthalmology 2011, 118:700-705.
82. Imasawa M., Ohshiro T., Gotoh T., et al. Central serous chorioretinopathy following vitrectomy with intravitreal triamcinolone acetonide for diabetic macular oedema. Acta Ophthalmol Scand 2005, 83:132-133.
83. Inoue M., Kadonosono K., Watanabe Y., et al. Results of one-year follow-up examinations after intravitreal bevacizumab administration for chronic central serous chorioretinopathy. Ophthalmologica 2011, 225:37-40.
84. Inoue R., Sawa M., Tsujikawa M., et al. Association between the efficacy of photodynamic therapy and indocyanine green angiography findings for central serous chorioretinopathy. Am J Ophthalmol 2010, 149:441-446. e1-2.
85. Jain A.K., Kaines A., Schwartz S. Bilateral central serous chorioretinopathy resolving rapidly with treatment for obstructive sleep apnea. Graefes Arch Clin Exp Ophthalmol 2010, 248:1037-1039.
86. Jain I.S., Singh K. Maculopathy a corticosteroid side-effect. J All India Ophthalmol Soc 1966, 14:250-252.
87. Jampol L.M., Weinreb R., Yannuzzi L. Involvement of corticosteroids and catecholamines in the pathogenesis of central serous chorioretinopathy: a rationale for new treatment strategies. Ophthalmology 2002, 109:1765-1766.
88. Karadimas P., Bouzas E.A. Glucocorticoid use represents a risk factor for central serous chorioretinopathy: a prospective, case-control study. Graefes Arch Clin Exp Ophthalmol 2004, 242:800-802.
89. Karadimas P., Kapetanios A., Bouzas E.A. Central serous chorioretinopathy after local application of glucocorticoids for skin disorders. Arch Ophthalmol 2004, 122:784-786.
90. Kassam A.A., White W., Ling R.H., et al. Loss of visual acuity due to central serous retinopathy after steroid injection into the shoulder bursa. J Shoulder Elbow Surg 2011, 20:e5-e6.
91. Kayazawa F. Central serous choroidopathy with exudative retinal detachment. Ann Ophthalmol 1982, 14:1035-1042.
92. Kim S.R., Nakanishi K., Itagaki Y., et al. Photooxidation of A2-PE, a photoreceptor outer segment fluorophore, and protection by lutein and zeaxanthin. Exp Eye Res 2006, 82:828-839.
93. Kim S.W., Oh J., Oh I.K., et al. Retinal pigment epithelial tear after half fluence PDT for serous pigment epithelial detachment in central serous chorioretinopathy. Ophthalmic Surg Lasers Imaging 2009, 40:300-303.
94. Kim S.W., Oh J., Huh K. Correlations among various functional and morphological tests in resolved central serous chorioretinopathy. Br J Ophthalmol 2011.
95. Kim S.W., Oh J., Kwon S.S., et al. Comparison of choroidal thickness among patients with healthy eyes, early age-related maculopathy, neovascular age-related macular degeneration, central serous chorioretinopathy, and polypoidal choroidal vasculopathy. Retina 2011, 31:1904-1911.
96. Kim S.W., Oh J., Huh K. Correlations among various functional and morphological tests in resolved central serous chorioretinopathy. Br J Ophthalmol 2012, 96:350-355.
97. Kitzmann A.S., Pulido J.S., Diehl N.N., Hodge D.O., Burke J.P. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980-2002. Ophthalmology 2008, 115:169-173.
98. Klein M.L., Van Buskirk E.M., Friedman E., et al. Experience with nontreatment of central serous choroidopathy. Arch Ophthalmol 1974, 91:247-250.
99. Kloos P., Laube I., Thoelen A. Obstructive sleep apnea in patients with central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 2008, 246:1225-1228.
100. Kocabora M.S., Durmaz S., Kandemir N. Exacerbation of central serous chorioretinopathy following intravitreal triamcinolone injection. Graefes Arch Clin Exp Ophthalmol 2008, 246:1783-1786.
101. Kon Y., Iida T., Maruko I., et al. The optical coherence tomography-ophthalmoscope for examination of central serous chorioretinopathy with precipitates. Retina 2008, 28:864-869.
102. Konstantinidis L., Mantel I., Zografos L., et al. Intravitreal ranibizumab in the treatment of choroidal neovascularization associated with idiopathic central serous chorioretinopathy. Eur J Ophthalmol 2010, 20:955-958.
103. Koskela P., Laatikainen L., von Dickhoff K. Contrast sensitivity after resolution of central serous retinopathy. Graefes Arch Clin Exp Ophthalmol 1994, 232:473-476.
104. Koytak A., Erol K., Coskun E., et al. Fluorescein angiography-guided photodynamic therapy with half-dose verteporfin for chronic central serous chorioretinopathy. Retina 2010, 30:1698-1703.
105. Lai T.Y., Chan W.M., Li H., et al. Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot study. Br J Ophthalmol 2006, 90:869-874.
106. Lai T.Y., Lai R.Y., Ngai J.W., et al. First- and second-order kernel multifocal electroretinography abnormalities in acute central serous chorioretinopathy. Doc Ophthalmol 2008, 116:29-40.
107. Leaver P., Williams C. Argon laser photocoagulation in the treatment of central serous retinopathy. Br J Ophthalmol 1979, 63:674-677.
108. Lee J.Y., Chae J.B., Yang S.J., et al. Intravitreal bevacizumab versus the conventional protocol of photodynamic therapy for treatment of chronic central serous chorioretinopathy. Acta Ophthalmol 2011, 89:e293-e294.
109. Lee S.T., Adelman R.A. The treatment of recurrent central serous chorioretinopathy with intravitreal bevacizumab. J Ocul Pharmacol Ther 2011, 27(6):611-614.
110. Leveque T.K., Yu L., Musch D.C., et al. Central serous chorioretinopathy and risk for obstructive sleep apnea. Sleep Breath 2007, 11:253-257.
111. Levy J., Marcus M., Belfair N., et al. Central serous chorioretinopathy in patients receiving systemic corticosteroid therapy. Can J Ophthalmol 2005, 40:217-221.
112. Li X.J., Zhang J.S. Intravitreal bevacizumab injection for chronic central serous chorioretinopathy. Chin Med J (Engl) 2010, 123:2145-2147.
113. Lim J.W., Kim M.U., Shin M.C. Aqueous humor and plasma levels of vascular endothelial growth factor and interleukin-8 in patients with central serous chorioretinopathy. Retina 2010, 30:1465-1471.
114. Lim J.W., Ryu S.J., Shin M.C. The effect of intravitreal bevacizumab in patients with acute central serous chorioretinopathy. Korean J Ophthalmol 2010, 24:155-158.
115. Lim J.W., Kang S.W., Kim Y.T., et al. Comparative study of patients with central serous chorioretinopathy undergoing focal laser photocoagulation or photodynamic therapy. Br J Ophthalmol 2011, 95:514-517.
116. Lim J.W., Kim M.U. The efficacy of intravitreal bevacizumab for idiopathic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 2011, 249:969-974.
117. Lim S.J., Roh M.I., Kwon O.W. Intravitreal bevacizumab injection for central serous chorioretinopathy. Retina 2010, 30:100-106.
118. Lin E., Arrigg P.G., Kim R.Y. Familial central serous choroidopathy. Graefes Arch Clin Exp Ophthalmol 2000, 238:930-931.
119. Lin J.M., Tsai Y.Y. Retinal pigment epithelial detachment in the fellow eye of a patient with unilateral central serous chorioretinopathy treated with steroid. Retina 2001, 21:377-379.
120. Loo R.H., Scott I.U., Flynn H.W., et al. Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy. Retina 2002, 22:19-24.
121. Maaranen T.H., Tuppurainen K.T., Mantyjarvi M.I. Color vision defects after central serous chorioretinopathy. Retina 2000, 20:633-637.
122. Mandal S., Sinha S., Abbas Z., et al. Intravitreal bevacizumab for subfoveal choroidal neovascularization complicating active central serous chorioretinopathy. Indian J Ophthalmol 2011, 59:338-339.
123. Mansuetta C.C., Mason J.O., Swanner J., et al. An association between central serous chorioretinopathy and gastroesophageal reflux disease. Am J Ophthalmol 2004, 137:1096-1100.
124. Margolis R., Spaide R.F. A pilot study of enhanced depth imaging optical coherence tomography of the choroid in normal eyes. Am J Ophthalmol 2009, 147:811-815.
125. Marmor M.F., Tan F. Central serous chorioretinopathy: bilateral multifocal electroretinographic abnormalities. Arch Ophthalmol 1999, 117:184-188.
126. Maruko I., Iida T., Sugano Y., et al. Subfoveal choroidal thickness after treatment of central serous chorioretinopathy. Ophthalmology 2010, 117:1792-1799.
127. Maruko I., Iida T., Ojima A., et al. Subretinal dot-like precipitates and yellow material in central serous chorioretinopathy. Retina 2011, 31:759-765.
128. Maruko I., Iida T., Sugano Y., et al. One-year choroidal thickness results after photodynamic therapy for central serous chorioretinopathy. Retina 2011, 31(9):1921-1927.
129. Maruko I., Iida T., Sugano Y., et al. Subfoveal choroidal thickness in fellow eyes of patients with central serous chorioretinopathy. Retina 2011, 31:1603-1608.
130. Maruko I., Iida T., Sugano Y., et al. Subfoveal retinal and choroidal thickness after verteporfin photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 2011, 151:594-603. e1.
131. Matsumoto H., Kishi S., Otani T., et al. Elongation of photoreceptor outer segment in central serous chorioretinopathy. Am J Ophthalmol 2008, 145:162-168.
132. Matsumoto H., Sato T., Kishi S. Outer nuclear layer thickness at the fovea determines visual outcomes in resolved central serous chorioretinopathy. Am J Ophthalmol 2009, 148:105-110. e1.
133. Matsumoto H., Kishi S., Sato T., et al. Fundus autofluorescence of elongated photoreceptor outer segments in central serous chorioretinopathy. Am J Ophthalmol 2011, 151:617-623. e1.
134. Mauget-Faysse M., Kodjikian L., Quaranta M., et al. [Helicobacter pylori in central serous chorioretinopathy and diffuse retinal epitheliopathy. Results of the first prospective pilot study]. J Fr Ophtalmol 2002, 25:1021-1025.
135. Maumenee A.E. Symposium: macular diseases, clinical manifestations. Trans Am Acad Ophthalmol Otolaryngol 1965, 69:605-613.
136. Meyerle C.B., Freund K.B., Bhatnagar P., et al. Ketoconazole in the treatment of chronic idiopathic central serous chorioretinopathy. Retina 2007, 27:943-946.
137. Meyerle C.B., Spaide R.F. Central serous chorioretinopathy. Albert & Jakobiec's Principles & Practice of Ophthalmology 2008, Saunders, Philadelphia, PA, ed 3. pp 1871-80. D.M.J. Albert, D. Azar, B. Blodi (Eds.).
138. Michael J.C., Pak J., Pulido J., et al. Central serous chorioretinopathy associated with administration of sympathomimetic agents. Am J Ophthalmol 2003, 136:182-185.
139. Misiuk-Hojlo M., Michalowska M., Turno-Krecicka A. Helicobacter pylori--a risk factor for the developement of the central serous chorioretinopathy. Klin Oczna 2009, 111:30-32.
140. Mitarai K., Gomi F., Tano Y. Three-dimensional optical coherence tomographic findings in central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 2006, 244:1415-1420.
141. Mitsui Y., Matsubara M., Kanagawa M. [Xenon light exposure as a treatment of central serous retinopathy (a preliminary report)]. Nippon Ganka Kiyo 1969, 20:291-294.
142. Mondal L.K., Sarkar K., Datta H., et al. Acute bilateral central serous chorioretinopathy following intra-articular injection of corticosteroid. Indian J Ophthalmol 2005, 53:132-134.
143. Montero J.A., Ruiz-Moreno J.M. Optical coherence tomography characterisation of idiopathic central serous chorioretinopathy. Br J Ophthalmol 2005, 89:562-564.
144. Montero J.A., Ruiz-Moreno J.M., Fernandez-Munoz M. Intravitreal bevacizumab to treat choroidal neovascularization following photodynamic therapy in central serous choroidopathy. Eur J Ophthalmol 2011, 21(4):503-505.
145. Moon J.W., Yu H.G., Kim T.W., et al. Prognostic factors related to photodynamic therapy for central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 2009, 247:1315-1323.
146. Moschos M., Brouzas D., Koutsandrea C., et al. Assessment of central serous chorioretinopathy by optical coherence tomography and multifocal electroretinography. Ophthalmologica 2007, 221:292-298.
147. Mudvari S.S., Goff M.J., Fu A.D., et al. The natural history of pigment epithelial detachment associated with central serous chorioretinopathy. Retina 2007, 27:1168-1173.
148. Negi A., Marmor M.F. Experimental serous retinal detachment and focal pigment epithelial damage. Arch Ophthalmol 1984, 102:445-449.
149. Nielsen J.S., Jampol L.M. Oral mifepristone for chronic central serous chorioretinopathy. Retina 2011, 31:1928-1936.
150. Oh J., Smiddy W.E., Flynn H.W., et al. Photoreceptor inner/outer segment defect imaging by spectral domain OCT and visual prognosis after macular hole surgery. Invest Ophthalmol Vis Sci 2010, 51:1651-1658.
151. Oikarinen A.I., Uitto J., Oikarinen J. Glucocorticoid action on connective tissue: from molecular mechanisms to clinical practice. Med Biol 1986, 64:221-230.
152. Oishi A., Otani A., Sasahara M., et al. Photoreceptor integrity and visual acuity in cystoid macular oedema associated with retinitis pigmentosa. Eye 2009, 23(6):1411-1416.
153. Ojima Y., Hangai M., Sasahara M., et al. Three-dimensional imaging of the foveal photoreceptor layer in central serous chorioretinopathy using high-speed optical coherence tomography. Ophthalmology 2007, 114(12):2197-2207.
154. Ojima Y., Tsujikawa A., Hangai M., et al. Retinal sensitivity measured with the micro perimeter 1 year after resolution of central serous chorioretinopathy. Am J Ophthalmol 2008, 146:77-84.
155. Okushiba U., Takeda M. [Study of choroidal vascular lesions in central serous chorioretinopathy using indocyanine green angiography]. Nihon Ganka Gakkai Zasshi 1997, 101:74-82.
156. Oosterhuis J.A. Familial central serous retinopathy. Graefes Arch Clin Exp Ophthalmol 1996, 234:337-341.
157. Ooto S., Hangai M., Sakamoto A., et al. High-resolution imaging of resolved central serous chorioretinopathy using adaptive optics scanning laser ophthalmoscopy. Ophthalmology 2010, 117:1800-1809. 9 e1-2.
158. Ozdemir H., Karacorlu S.A., Senturk F., et al. Assessment of macular function by microperimetry in unilateral resolved central serous chorioretinopathy. Eye (Lond) 2008, 22:204-208.
159. Ozmert E., Batioglu F. Fundus autofluorescence before and after photodynamic therapy for chronic central serous chorioretinopathy. Ophthalmologica 2009, 223:263-268.
160. Park D.W., Schatz H., Gaffney M.M., et al. Central serous chorioretinopathy in two families. Eur J Ophthalmol 1998, 8:42-47.
161. Peabody R.R., Zweng H.C., Little H.L. Treatment of persistent central serous retinopathy. Arch Ophthalmol 1968, 79:166-169.
162. Piccolino F.C., de la Longrais R.R., Ravera G., et al. The foveal photoreceptor layer and visual acuity loss in central serous chorioretinopathy. Am J Ophthalmol 2005, 139:87-99.
163. Pikkel J., Beiran I., Ophir A., et al. Acetazolamide for central serous retinopathy. Ophthalmology 2002, 109:1723-1725.
164. Pikkel J., Rumelt S. Intravitreal bevacizumab for choroidal neovascularization secondary to laser photocoagulation for central serous chorioretinopathy. Eur J Ophthalmol 2012, 22(3):488-491.
165. Polak B.C., Baarsma G.S., Snyers B. Diffuse retinal pigment epitheliopathy complicating systemic corticosteroid treatment. Br J Ophthalmol 1995, 79:922-925.
166. Prunte C., Flammer J. Choroidal capillary and venous congestion in central serous chorioretinopathy. Am J Ophthalmol 1996, 121:26-34.
167. Rahbani-Nobar M.B., Javadzadeh A., Ghojazadeh L., et al. The effect of Helicobacter pylori treatment on remission of idiopathic central serous chorioretinopathy. Mol Vis 2011, 17:99-103.
168. Ravage Z., Packo K. Rifampin for treatment of central serous chorioretinopathy. ARVO 2011 2011, Ft, Lauderdale, FL.
169. Reibaldi M, Cardascia N, Longo A, et al. Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial. Am J Ophthalmol. 149:307-15.
170. Reibaldi M., Cardascia N., Longo A., et al. Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial. Am J Ophthalmol 2010, 149:307-315.
171. Reibaldi M., Boscia F., Avitabile T., et al. Functional retinal changes measured by microperimetry in standard-fluence vs low-fluence photodynamic therapy in chronic central serous chorioretinopathy. Am J Ophthalmol 2011, 151:953-960. e2.
172. Ricci F., Missiroli F., Cerulli L. Indocyanine green dye-enhanced micropulsed diode laser: a novel approach to subthreshold RPE treatment in a case of central serous chorioretinopathy. Eur J Ophthalmol 2004, 14:74-82.
173. Ricci F., Missiroli F., Regine F., et al. Indocyanine green enhanced subthreshold diode-laser micropulse photocoagulation treatment of chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 2009, 247:597-607.
174. Robertson D.M., Ilstrup D. Direct, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy. Am J Ophthalmol 1983, 95:457-466.
175. Roisman L., Lavinsky D., Magalhaes F., et al. Fundus autofluorescence and spectral domain oct in central serous chorioretinopathy. J Ophthalmol 2011, 2011:706849.
176. Ross A., Ross A.H., Mohamed Q. Review and update of central serous chorioretinopathy. Curr Opin Ophthalmol 2011, 22:166-173.
177. Rouvas A., Stavrakas P., Theodossiadis P.G., et al. Long-term results of half-fluence photodynamic therapy for chronic central serous chorioretinopathy. Eur J Ophthalmol 2012, 22(3):417-422.
178. Ruiz-Moreno J.M., Lugo F.L., Armada F., et al. Photodynamic therapy for chronic central serous chorioretinopathy. Acta Ophthalmol 2010, 88:371-376.
179. Sakaue M., Hoffman B.B. Glucocorticoids induce transcription and expression of the alpha 1B adrenergic receptor gene in DTT1 MF-2 smooth muscle cells. J Clin Invest 1991, 88:385-389.
180. Sandle G.I., McGlone F. Acute effects of dexamethasone on cation transport in colonic epithelium. Gut 1987, 28:701-706.
181. Schaal K.B., Hoeh A.E., Scheuerle A., et al. Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy. Eur J Ophthalmol 2009, 19:613-617.
182. Schmidt-Erfurth U., Michels S., Barbazetto I., et al. Photodynamic effects on choroidal neovascularization and physiological choroid. Invest Ophthalmol Vis Sci 2002, 43:830-841.
183. Schmitz-Valckenberg S., Holz F.G., Bird A.C., et al. Fundus autofluorescence imaging: review and perspectives. Retina 2008, 28:385-409.
184. Sekiryu T., Iida T., Maruko I., et al. Infrared fundus autofluorescence and central serous chorioretinopathy. Invest Ophthalmol Vis Sci 2010, 51:4956-4962.
185. Senturk F., Karacorlu M., Ozdemir H., et al. Microperimetric changes after photodynamic therapy for central serous chorioretinopathy. Am J Ophthalmol 2011, 151:303-309. e1.
186. Seong H.K., Bae J.H., Kim E.S., et al. Intravitreal bevacizumab to treat acute central serous chorioretinopathy: short-term effect. Ophthalmologica 2009, 223:343-347.
187. Sharma T., Shah N., Rao M., et al. Visual outcome after discontinuation of corticosteroids in atypical severe central serous chorioretinopathy. Ophthalmology 2004, 111:1708-1714.
188. Sharma T., Parikh S.D. Transpupillary thermotherapy for juxtafoveal leak in central serous chorioretinopathy. Ophthalmic Surg Lasers Imaging 2010, 1-3. E-Pub ahead of Print. doi: 10.3928/15428877-20100215-23.
189. Shin J.Y., Woo S.J., Yu H.G., et al. Comparison of efficacy and safety between half-fluence and full-fluence photodynamic therapy for chronic central serous chorioretinopathy. Retina 2011, 31:119-126.
190. Shin M.C., Lim J.W. Concentration of cytokines in the aqueous humor of patients with central serous chorioretinopathy. Retina 2011, 31:1937-1943.
191. Shinojima A., Kawamura A., Mori R., et al. Detection of morphologic alterations by spectral-domain optical coherence tomography before and after half-dose verteporfin photodynamic therapy in chronic central serous chorioretinopathy. Retina 2011, 31:1912-1920.
192. Shukla D., Kolluru C., Vignesh T.P., et al. Transpupillary thermotherapy for subfoveal leaks in central serous chorioretinopathy. Eye (Lond) 2008, 22:100-106.
193. Sibayan S.A., Kobuch K., Spiegel D., et al. Epinephrine, but not dexamethasone, induces apoptosis in retinal pigment epithelium cells in vitro: possible implications on the pathogenesis of central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 2000, 238:515-519.
194. Sivaprasad S., Elagouz M., McHugh D., et al. Micropulsed diode laser therapy: evolution and clinical applications. Surv Ophthalmol 2010, 55:516-530.
195. Smith P.R., Benos D.J. Epithelial Na+ channels. Annu Rev Physiol 1991, 53:509-530.
196. Spahn C., Wiek J., Burger T., et al. Psychosomatic aspects in patients with central serous chorioretinopathy. Br J Ophthalmol 2003, 87:704-708.
197. Spaide R. Autofluorescence from the outer retina and subretinal space: hypothesis and review. Retina 2008, 28:5-35.
198. Spaide R.F., Campeas L., Haas A., et al. Central serous chorioretinopathy in younger and older adults. Ophthalmology 1996, 103:2070-2079. discussion 9-80.
199. Spaide R.F., Hall L., Haas A., et al. Indocyanine green videoangiography of older patients with central serous chorioretinopathy. Retina 1996, 16:203-213.
200. Spaide R.F. Fundus autofluorescence and age-related macular degeneration. Ophthalmology 2003, 110:392-399.
201. Spaide R.F., Klancnik J.M. Fundus autofluorescence and central serous chorioretinopathy. Ophthalmology 2005, 112:825-833.
202. Spaide R.F., Koizumi H., Pozzoni M.C. Enhanced depth imaging spectral-domain optical coherence tomography. Am J Ophthalmol 2008, 146:496-500.
203. Spitznas M. Pathogenesis of central serous retinopathy: a new working hypothesis. Graefes Arch Clin Exp Ophthalmol 1986, 224:321-324.
204. Spitznas M., Huke J. Number, shape, and topography of leakage points in acute type I central serous retinopathy. Graefes Arch Clin Exp Ophthalmol 1987, 225:437-440.
205. Steinle N.C., Gupta N., Yuan A., et al. Oral rifampin utilisation for the treatment of chronic multifocal central serous retinopathy. Br J Ophthalmol 2012, 96(1):10-13.
206. Steinsapir K.D., Tripathi R.C., Tripathi B.J., et al. Inhibition of ocular gamma glutamyl transpeptidase by acetazolamide. Exp Eye Res 1992, 55:179-181.
207. Sun J., Tan J., Wang Z., et al. Effect of catecholamine on central serous chorioretinopathy. J Huazhong Univ Sci Technolog Med Sci 2003, 23:313-316.
208. Suzuki K., Hasegawa S., Usui T., et al. Multifocal electroretinogram in central serous chorioretinopathy. Jpn J Ophthalmol 2000, 44:571.
209. Suzuki K., Hasegawa S., Usui T., et al. Multifocal electroretinogram in patients with central serous chorioretinopathy. Jpn J Ophthalmol 2002, 46:308-314.
210. Taban M., Boyer D.S., Thomas E.L. Chronic central serous chorioretinopathy: photodynamic therapy. Am J Ophthalmol 2004, 137:1073-1080.
211. Tewari H.K., Gadia R., Kumar D., et al. Sympathetic-parasympathetic activity and reactivity in central serous chorioretinopathy: a case-control study. Invest Ophthalmol Vis Sci 2006, 47:3474-3478.
212. Tittl M., Polska E., Kircher K., et al. Topical fundus pulsation measurement in patients with active central serous chorioretinopathy. Arch Ophthalmol 2003, 121:975-978.
213. Tittl M., Maar N., Polska E., et al. Choroidal hemodynamic changes during isometric exercise in patients with inactive central serous chorioretinopathy. Invest Ophthalmol Vis Sci 2005, 46:4717-4721.
214. Tittl M.K., Spaide R.F., Wong D., et al. Systemic findings associated with central serous chorioretinopathy. Am J Ophthalmol 1999, 128:63-68.
215. Torres-Soriano M.E., Garcia-Aguirre G., Kon-Jara V., et al. A pilot study of intravitreal bevacizumab for the treatment of central serous chorioretinopathy (case reports). Graefes Arch Clin Exp Ophthalmol 2008, 246:1235-1239.
216. Uyama M., Matsunaga H., Matsubara T., et al. Indocyanine green angiography and pathophysiology of multifocal posterior pigment epitheliopathy. Retina 1999, 19:12-21.
217. Vajaranant T.S., Szlyk J.P., Fishman G.A., et al. Localized retinal dysfunction in central serous chorioretinopathy as measured using the multifocal electroretinogram. Ophthalmology 2002, 109:1243-1250.
218. Verma L., Sinha R., Venkatesh P., et al. Comparative evaluation of diode laser versus argon laser photocoagulation in patients with central serous retinopathy: a pilot, randomized controlled trial [ISRCTN84128484]. BMC Ophthalmol 2004, 4:15.
219. von Graefe A. Ueber centrale recidivierende retinitis. Graefes Arch Clin Exp Ophthalmol 1866, 12:211-215.
220. von Winning C.H., Oosterhuis J.A., Renger-van Dijk A.H., et al. Diffuse retinal pigment epitheliopathy. Ophthalmologica 1982, 185:7-14.
221. Wakakura M., Ishikawa S. Central serous chorioretinopathy complicating systemic corticosteroid treatment. Br J Ophthalmol 1984, 68:329-331.
222. Weenink A.C., Borsje R.A., Oosterhuis J.A. Familial chronic central serous chorioretinopathy. Ophthalmologica 2001, 215:183-187.
223. Wei S.Y., Yang C.M. Transpupillary thermotherapy in the treatment of central serous chorioretinopathy. Ophthalmic Surg Lasers Imaging 2005, 36:412-415.
224. Williams M.A., Mulholland C., Silvestri G. Photodynamic therapy for central serous chorioretinopathy using a reduced dose of verteporfin. Can J Ophthalmol 2008, 43:123.
225. Williamson J., Nuki G. Macular lesions during systemic therapy with depot tetracosactrin. Br J Ophthalmol 1970, 54:405-409.
226. Wolfensberger T.J., Chiang R.K., Takeuchi A., et al. Inhibition of membrane-bound carbonic anhydrase enhances subretinal fluid absorption and retinal adhesiveness. Graefes Arch Clin Exp Ophthalmol 2000, 238:76-80.
227. Wu Z.H., Lai R.Y., Yip Y.W., et al. Improvement in multifocal electroretinography after half-dose verteporfin photodynamic therapy for central serous chorioretinopathy: a randomized placebo-controlled trial. Retina 2011, 31:1378-1386.
228. Wyman G.J. Central serous retinopathy in twins. Am J Ophthalmol 1963, 55:1265.
229. Wynn P.A. Idiopathic central serous chorioretinopathy-a physical complication of stress?. Occup Med (Lond) 2001, 51:139-140.
230. Yamada R., Yamada S., Ishii A., et al. [Evaluation of tissue plasminogen activator and plasminogen activator inhibitor-1 in blood obtained from patients of idiopathic central serous chorioretinopathy]. Nippon Ganka Gakkai Zasshi 1993, 97:955-960.
231. Yang S., Zhang L. Glucocorticoids and vascular reactivity. Curr Vasc Pharmacol 2004, 2:1-12.
232. Yannuzzi L.A. Type A behavior and central serous chorioretinopathy. Trans Am Ophthalmol Soc 1986, 84:799-845.
233. Yannuzzi L.A. Type-A behavior and central serous chorioretinopathy. Retina 1987, 7:111-131.
234. Yannuzzi L.A., Slakter J.S., Kaufman S.R., et al. Laser treatment of diffuse retinal pigment epitheliopathy. Eur J Ophthalmol 1992, 2:103-114.
235. Yannuzzi L.A., Slakter J.S., Gross N.E., et al. Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina 2003, 23:288-298.
236. Yannuzzi L.A. Central serous chorioretinopathy: a personal perspective. Am J Ophthalmol 2010, 149:361-363.
237. Yip Y.W., Ngai J.W., Fok A.C., et al. Correlation between functional and anatomical assessments by multifocal electroretinography and optical coherence tomography in central serous chorioretinopathy. Doc Ophthalmol 2010, 120:193-200.
238. Yoshioka H., Katsume Y. [Studies on experimental central serous chorioretinopathy. A light and electron microscopy]. Nihon Ganka Gakkai Zasshi 1982, 86:738-749.
239. Yoshioka H., Katsume Y., Akune H. Experimental central serous chorioretinopathy in monkey eyes: fluorescein angiographic findings. Ophthalmologica 1982, 185:168-178.
240. Yoshioka H. [The etiology of central serous chorioretinopathy]. Nihon Ganka Gakkai Zasshi 1991, 95:1181-1195.
241. Zakir S.M., Shukla M., Simi Z.U., et al. Serum cortisol and testosterone levels in idiopathic central serous chorioretinopathy. Indian J Ophthalmol 2009, 57:419-422.
242. Zhao M.W., Zhou P., Xiao H.X., et al. Photodynamic therapy for acute central serous chorioretinopathy: the safe effective lowest dose of verteporfin. Retina 2009, 29:1155-1161.